Evommune, Inc. (EVMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evommune, Inc. (EVMN) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.70 Million) by net assets ($205.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Evommune, Inc. balance sheet independence to measure how much of total assets are equity-financed.
Evommune, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Evommune, Inc.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Evommune, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evommune, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
People & Technology Inc
KQ:137400
|
0.023x |
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
0.078x |
|
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
|
-0.191x |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
-0.007x |
|
Beijing InterAct Technology Co Ltd
SHE:300419
|
0.054x |
|
Tianjin Tianbao Infrastructure Co Ltd
SHE:000965
|
0.025x |
|
Chin-Poon Industrial Co Ltd
TW:2355
|
0.016x |
|
SA Corporate Real Estate Fund Managers Ltd
JSE:SAC
|
0.023x |
Annual Cash Flow Conversion Efficiency for Evommune, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of Evommune, Inc. from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see EVMN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $205.57 Million | $-76.44 Million | -0.372x | -192.17% |
| 2024-12-31 | $-144.24 Million | $-58.20 Million | 0.403x | +4.62% |
| 2023-12-31 | $-77.71 Million | $-29.97 Million | 0.386x | -- |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more